4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

4 - Evolus, Inc. (0001570562) (Issuer)

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in June of non-qualified stock options to purchase an aggregate of 11,628 shares of Evolus and an aggregate of 36,077 restricted stock units (RSUs) of the company's common stock to 17 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of June 8, 2025 and vesting commencement date of June 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accor

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, is proud to announce it has been recognized with two Shape 2025 Skin Awards: Evolysse™ Recognized as the Best Filler for 2025 with its recently launched injectable hyaluronic acid gel line Best Membership Treatment Model for Club Evolus™, its proprietary consumer rewards program The annual Shape Skin Awards highlight innovation and performance across the skincare and aesthetics industry. This year the judging panel of board-certified dermatologists and specialists evaluated more than 800 products and treatments, ultimately selecting winners across a range of

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resigned effective June 13, 2025, to accept the same position at a private mental health and wellness technology company. Ms. Beaver's resignation is not a result of any disagreement related to the company's operations, policies or practices, including any accounting principles and practices, or related to any financial statements or disclosures. "On behalf of our employees, our leadership team, and our Board of Directors, I want to thank Sandra for her contributions to Evolus," said David Moatazed

Data showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statistical superiority1 to Restylane®-L, the control product The study published in Aesthetic Surgery Journal supports long-term safety and effectiveness of Cold-X™ crosslinked injectable hyaluronic acid (HA) gels for the correction of dynamic facial wrinkles and folds Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of the U.S. pivotal study results for Evolysse™ Form and Evolysse™ Smooth in the Aesthetic Surgery Journal, a leading peer-reviewed journal focusi

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in May of non-qualified stock options to purchase an aggregate of 12,706 shares of Evolus and an aggregate of 40,576 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant date of May 12, 2025 and vesting commencement date of May 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accorda

Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in April of an aggregate of 30,579 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of April 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the v

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th. To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion l

144 - Evolus, Inc. (0001570562) (Subject)

8-K - Evolus, Inc. (0001570562) (Filer)

8-K - Evolus, Inc. (0001570562) (Filer)

SCHEDULE 13G - Evolus, Inc. (0001570562) (Subject)

SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

SCHEDULE 13G/A - Evolus, Inc. (0001570562) (Subject)

10-Q - Evolus, Inc. (0001570562) (Filer)

8-K - Evolus, Inc. (0001570562) (Filer)

8-K - Evolus, Inc. (0001570562) (Filer)

DEF 14A - Evolus, Inc. (0001570562) (Filer)